Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2594-2600

  Luo, Jin Cai ^a   Toyoda, Masashi ^a   Shibuya, Masabumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID; ASCITES TUMOR; BREAST ADENOCARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ASCITES; ASCITIC FLUID; CAPILLARY PERMEABILITY; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; LYMPHOKINES; MALE; MICE; MICE, INBRED C3H; NEOPLASM PROTEINS; PERITONEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0347377779     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Holm-Nielsen, P. Pathogenesis of ascites in peritoneal carcinomatosis. Acta Pathol. Microbiol. Scand., 33: 10-21, 1953.
2. Feldman, G. B., Knapp, R. C., Order, S. E., and Hellman, S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res., 32: 1663-1666, 1972.
3. 99mTc-sulfur colloid. Radiology, 107: 577-583, 1973.
4. Feldman, G. B., Knapp, R. C. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am. J. Obstet. Gynecol., 119: 991-994, 1974.
5. Brown, H. R. Kinetics of angiogenesis in small vessels related to mouse parietal peritoneum. Anat. Rec., 184: 364, 1976.
6. Heuser, L. S., Taylor, S. H., and Folkman, J. Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis. J. Surg. Res., 36: 244-250, 1984.
7. Straube, R. L. Fluid accumulation during initial stages tumor growth. Cancer Res., 18: 57-65, 1958.
8. Hirabayashi, K., and Graham, J. Genesis of ascites in ovarian cancer. Am. J. Obstet. Gynecol., 106: 492-497, 1970.
9. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.
10. Garrison, R. N., Kaelin, L. D., Heuser, L. S., and Galloway, R. H. Malignant ascites clinical and experimental observations. Ann. Surg., 203: 644-649, 1986.
11. Garrison, R. N., Galloway, R. H., and Heuser, L. S. Mechanisms of malignant ascites production. J. Surg. Res., 42: 126-132, 1987.
12. Sykes, A. C. Pharmacologically active substances in malignant ascites fluid. Br. J. Pharmacol., 40: 595P-596P, 1970.
13. Greenbaum, L. M., Grebow, P., Johnston, Prakash, A., and Semente, G. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation. Cancer Res., 35: 706-710, 1975.
14. 3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem., 263: 16051-16054, 1988.
15. Matsumura, Y., Kimura, M., Yamamoto, T., and Maeda, H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res., 79: 1327-1334, 1988.
16. Matsumura, Y., Maruo, Kimura, M., Yamamoto, T., Konno, T., and Maeda, H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res., 82: 732-741, 1991.
17. White, M. J., Miller, F. N., Heuser, L. S., and Pietsch, C. G. Human malignant ascites and histamine-induced protein leakage from the normal microcirculation. Microvasc. Res., 35: 63-72, 1988.
18. Maeda, H., Noguchi, Y., Sato, K., and Akaike, T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res., 85: 331-334, 1994.
19. Ettinghausen, S. E., Puri, R. J., and Rosenberg, S. A. Enhanced vascular permeability in organs mediated by the systemic administration of lymphokine-activaled killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst., 80: 177-187, 1988.
20. Ohmura, E., Tsushima, T., Kamiya, Y., Okada, M., Onoda, N., Shizume, K., and Demura, H. Epidermal growth factor and transforming growth factor alpha induce ascitic fluid in mice. Cancer Res., 50: 4915-4917, 1990.
21. Nagy, J. A., Morgan, E. S., Herzberg, K. T., Manseau, E. J., Dvorak, A. M., and Dvorak, H. F. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res., 55: 376-385, 1995.
22. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., Siossat, and Dvorak, H. F., Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res., 55: 360-368, 1995.
23. Yeo, K. T., Wang, H. H., Nagy, J. A., Scioussat, T. M., Ledbetter, S. R., Hoogewerf, A. J., Zhou, Y., Masse, E. M., Senger, D. R., Dvorak, and Yeo, T. K. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res., 53: 2912-2918, 1993.
24. Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Ana, S., Manseau, E. J., Water, L. VD, and Senger, D. R. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med., 174: 1275-1278, 1991.
25. Luo, J. C., Yamaguchi, S., Shinkai, A., Shitara, K., and Shibuya, M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res., 58: 2652-2660, 1998.
26. Takeuchi, S., Irie, R. F., Inoue, M., Irie, K., Izumi, R., and Nishioka, K. Immunological studies on mouse mammary tumors. II. Characterization of tumor-specific antibodies against mouse mammary tumors. Int. J. Cancer, 4: 130-138, 1969.
27. Nishioka, K., Irie, R. F., Takashi, K., Takeuchi, S. Immunological studies on mouse mammary tumors. III. Surface antigens reacting with tumor-specific antibodies in immune adherence. Int. J. Cancer, 4: 139-149, 1969.
28. Tanino, T., and Tsumita, T. Studies on the tumor-host relationship. Jpn. J. Exp. Med., 42: 401-413, 1972.
29. Davies, M. R., Lambert, L. P., Marshall, R. D. L-Asparaginyl-tRNA synthetase and L-asparaginyl-tRNA synthetase activities of L-asparaginase-sensitive and -resistant forms of the mouse Gardner lymphoma 6C3HED. Clin. Sci., 56: 539-545, 1979.
30. Kamisaki, Y., Wada, H., Yagura, T., Nishimura, H., Matsushima, A., and Inada, Y. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol. Gann, 73: 470-474, 1982.
31. Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, M., and Shibuya, M. Flt-1, but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ., 7: 213-221, 1996.